Developer docs
API playgroundTry for free, no card

Search company profiles

Oncobit

Full company profile

uuid0000m7l

Namestring
Oncobit
Legal namestring
oncobit AG
Websiteurl
oncobit.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Oncobit AG is a Swiss precision oncology company that develops digital PCR-based liquid biopsy tests and accompanying cloud-based analysis software for non-invasive cancer monitoring. Founded as a spin-off from the University of Zurich and ETH Zurich, the company is headquartered in Schlieren, Switzerland and operates with a small core team of approximately 10-15 employees including co-founders, scientists, data scientists, and software developers.

The company's product portfolio centers on the Oncobit PM (Personalized Monitoring) platform, which detects circulating tumor DNA (ctDNA) from patient blood samples to monitor cancer progression and treatment response. Core products include a CE-IVDR marked digital PCR assay panel covering five melanoma markers (BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209), the CE-marked Oncobit PM Analyzer software accessed via the Oncobit Portal, and Oncular, a uveal melanoma monitoring solution launched in the US market in 2026 through laboratory partner TrilliumBiO. All assays are designed to run on Bio-Rad QX200/QX600 digital PCR infrastructure, with sub-24-hour turnaround times.

Oncobit generates revenue through a combination of one-time assay sales to clinical laboratories and hospitals, recurring software platform access fees via the Oncobit Portal, and transaction-based laboratory services through TrilliumBiO in the US. Distribution is handled through direct enterprise sales and channel partnerships, notably Kempf und Pfaltz in Switzerland and TrilliumBiO in the US. The company targets three primary customer segments: pharmaceutical companies (for clinical trial monitoring and companion diagnostics), clinical laboratories (validated CE-IVDR assays), and hospitals and oncology clinics (treatment decision support). The company first generated revenue in Europe in 2024 and expanded into the US market via the TrilliumBiO partnership in 2026.

Short descriptiontext

Oncobit AG is a Swiss precision oncology company developing digital PCR-based liquid biopsy assays and cloud-based analysis software for non-invasive monitoring of cancer patients, with initial focus on melanoma and uveal melanoma for clinical laboratories, hospitals, and pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, ctDNA monitoring assays, digital PCR oncology, cancer molecular diagnostics, personalized cancer monitoring
Industry6 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Molecular Diagnostics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Assays
TypeOne Time License
Description

Sale of cancer monitoring assay kits for melanoma and other cancer types. Tests detect specific genetic mutations using digital PCR technology from patient blood samples.

venturelab.swiss
2Software Platform Access
TypeSubscription Recurring
Description

Oncobit Portal provides secure access to the Oncobit Analyzer software for data analysis. Revenue generated through software licensing and platform access fees.

oncobit.com
3Laboratory Services
TypeTransaction Fee
Description

Through TrilliumBiO partnership in US, Oncobit provides testing services via multi-accredited laboratory, enabling physicians to order monitoring tests without local infrastructure.

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1B2B enterprise pricing for laboratories and hospitals
ModelOtherBilling cadencePay-as-you-go
Notes

Contact-based pricing; assays sold to laboratories and clinical partners. Regulatory status: CE-IVDR marked for European market.

oncobit.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Oncular™
Description

Uveal melanoma monitoring solution launched in partnership with TrilliumBiO for the US market, enabling real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw.

prnewswire.com
+1 more record
Core offering1 text field

Oncobit develops and sells digital PCR-based liquid biopsy diagnostic assays combined with a CE-marked cloud analysis software (Oncobit PM Analyzer) for non-invasive cancer monitoring via circulating tumor DNA (ctDNA) detection from blood samples. The portfolio includes a five-marker melanoma panel (BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209), an uveal melanoma monitoring solution (Oncular™), and the Oncobit PM Personalized Monitoring platform, with CE-IVDR marking for the European market and US access via TrilliumBiO.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • <24 hour turnaround time for ctDNA analysis
+2 more records
Product overview1 text field

Oncobit offers a unified portfolio centered on the Oncobit™ PM (Personalized Monitoring) platform for precision cancer care. The platform combines liquid biopsy-based diagnostic assays (including a five-marker melanoma panel and uveal melanoma test) with cloud-based data analysis software (Oncobit PM Analyzer) accessed via the Oncobit Portal. All assays run on Bio-Rad digital PCR infrastructure and carry CE-IVDR marking for the European market, with Oncular™ representing the US market offering for uveal melanoma monitoring.

Product and service4 records
1Oncobit™ PM Platform
CategoryCancer Molecular Diagnostics Platform
Description

Cloud-based personalized monitoring platform for cancer care that analyzes circulating tumor DNA (ctDNA) from liquid biopsy blood samples. The platform provides molecular insights for precise cancer monitoring and therapy optimization using digital PCR technology, scalable across multiple cancer types.

2Oncobit™ PM Assays (Melanoma Panel)
CategoryDiagnostic Assay Kits
Description

Digital PCR-based diagnostic assays for detecting and quantifying five critical melanoma cancer markers including BRAF V600 (V600D, V600E, V600E2, V600K, V600R), NRAS Q61 (Q61K, Q61L, Q61R), GNAQ Q209 (Q209L, Q209P), and GNA11 Q209 mutations. CE-IVDR marked, runs on Bio-Rad QX200/QX600 platforms with <24-hour turnaround time.

3Oncobit PM Analyzer
CategoryCloud Analytics Software
Description

CE-marked proprietary cloud-based software designed to analyze data generated by Oncobit PM Assays. Accessed via the secure Oncobit Portal, providing standardized ctDNA data processing and reporting for clinical consistency.

4Oncular™
CategoryDiagnostic Test Service
Description

Uveal melanoma monitoring solution providing real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw. Made available in the US market through TrilliumBiO's multi-accredited laboratory partnership.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-09
Description

Strategic partnership to bring Oncobit's uveal melanoma monitoring solution (Oncular) to the United States. TrilliumBiO provides multi-accredited laboratory services for nationwide test availability. Collaboration integrates Oncobit's Personalized Monitoring platform with TrilliumBiO's laboratory infrastructure.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Strategic partnership combining ID Solutions' highly sensitive digital PCR biomarker detection technology with Oncobit's monitoring assays and analytical software. Aims to accelerate cancer diagnosis and enable more precise, real-time treatment monitoring in compliance with IVDR requirements.

3Kempf und Pfaltz
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-01
Description

Swiss laboratory distributor for Oncobit PM assays. Customers in Switzerland can place orders through Kempf und Pfaltz for product distribution.

oncobit.com
4EADO-EUMelaReg
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Joint ctDNA project integrating circulating tumor DNA into routine melanoma follow-up. Evaluates clinical utility of Oncobit's CE-IVDR marked digital PCR solution to detect relapse and complement established monitoring approaches.

oncobit.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

Oncobit is a HealthTech spin-off from University of Zurich. Founders are physicians and scientists from University Hospital Zurich and ETH Zurich. Ongoing research partnerships with clinical experts.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Natera is a publicly traded molecular diagnostics company with Signatera, a leading personalized ctDNA-based MRD/monitoring test for solid tumors. Comparable in target market (oncology monitoring) and business model (tumor-informed liquid biopsy), but with a much broader assay menu and substantially greater commercial scale than Oncobit.

TypeBroad incumbent
Description

Guardant Health offers Guardant360, one of the most widely used liquid biopsy comprehensive genomic profiling tests for advanced cancer, along with Guardant Reveal for MRD. Direct overlap in ctDNA-based oncology testing and biomarker monitoring, though Guardant operates at far greater scale using NGS rather than digital PCR.

TypeBroad incumbent
Description

Foundation Medicine is a leading provider of comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) for solid tumors. Overlaps with Oncobit in oncology molecular diagnostics and biopharma companion diagnostics; Oncobit's chairman Bram Goorden previously served as President of International Business at Foundation Medicine.

TypeBroad incumbent
Description

Exact Sciences, known for Cologuard and Oncotype DX, has been expanding into liquid biopsy-based MRD/monitoring through its Cologuard Plus and Precision Oncology portfolio. Comparable in oncology monitoring business model and B2B sales to clinicians and biopharma, though operating at much greater scale across multiple cancer types.

TypeBroad incumbent
Description

Roche Diagnostics is a global leader in in-vitro diagnostics, including the cobas digital PCR platform and cell-free DNA-based oncology assays. Overlaps with Oncobit in molecular oncology diagnostics and IVD commercialization; board member Dr. Daniel Schoener previously held corporate leadership at Roche Diagnostics.

TypeDirect peer
Description

Sysmex Inostics specializes in highly sensitive digital PCR-based liquid biopsy testing for oncology, including the SafeSEQ and OncoBEAM platforms for ctDNA detection in melanoma and other solid tumors. Direct competitor in digital PCR-based oncology monitoring, with established biopharma and clinical laboratory customers.

TypeBroad incumbent
Description

NeoGenomics provides oncology-focused clinical laboratory services including liquid biopsy assays for therapy selection and disease monitoring. Overlaps with Oncobit in offering ctDNA-based tests to oncologists and biopharma clients, but operates a much broader multi-modality testing menu.

8Inivata (NeoGenomics)
TypeDirect peer
Description

Inivata developed RaDaR, a tumor-informed personalized ctDNA MRD assay using digital PCR technology. Directly comparable to Oncobit's PM platform in technology (digital PCR-based ctDNA), use case (personalized cancer monitoring/MRD), and target customer (oncologists, biopharma). Now part of NeoGenomics.

TypeOthers
Description

Bio-Rad manufactures the QX200 and QX600 digital PCR systems on which Oncobit's PM Assays run. Comparable as enabling infrastructure for dPCR-based oncology testing; Bio-Rad also offers ddPCR reagents and certain assay kits for cell-free DNA research, partially overlapping with Oncobit's offering as a supplier/ecosystem partner.

10ID Solutions
TypeEmerging player
Description

ID Solutions develops highly sensitive digital PCR-based biomarker detection technology and is a strategic partner and investor in Oncobit. Comparable in dPCR technology focus and oncology applications, and now commercially aligned with Oncobit for IVDR-compliant precision oncology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncobit

Cancer Molecular Diagnosticsoncobit.com

Oncobit AG is a Swiss precision oncology company developing digital PCR-based liquid biopsy assays and cloud-based analysis software for non-invasive monitoring of cancer patients, with initial focus on melanoma and uveal melanoma for clinical laboratories, hospitals, and pharmaceutical partners.

What Oncobit does

Oncobit AG is a Swiss precision oncology company that develops digital PCR-based liquid biopsy tests and accompanying cloud-based analysis software for non-invasive cancer monitoring. Founded as a spin-off from the University of Zurich and ETH Zurich, the company is headquartered in Schlieren, Switzerland and operates with a small core team of approximately 10-15 employees including co-founders, scientists, data scientists, and software developers.

The company's product portfolio centers on the Oncobit PM (Personalized Monitoring) platform, which detects circulating tumor DNA (ctDNA) from patient blood samples to monitor cancer progression and treatment response. Core products include a CE-IVDR marked digital PCR assay panel covering five melanoma markers (BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209), the CE-marked Oncobit PM Analyzer software accessed via the Oncobit Portal, and Oncular, a uveal melanoma monitoring solution launched in the US market in 2026 through laboratory partner TrilliumBiO. All assays are designed to run on Bio-Rad QX200/QX600 digital PCR infrastructure, with sub-24-hour turnaround times.

Oncobit generates revenue through a combination of one-time assay sales to clinical laboratories and hospitals, recurring software platform access fees via the Oncobit Portal, and transaction-based laboratory services through TrilliumBiO in the US. Distribution is handled through direct enterprise sales and channel partnerships, notably Kempf und Pfaltz in Switzerland and TrilliumBiO in the US. The company targets three primary customer segments: pharmaceutical companies (for clinical trial monitoring and companion diagnostics), clinical laboratories (validated CE-IVDR assays), and hospitals and oncology clinics (treatment decision support). The company first generated revenue in Europe in 2024 and expanded into the US market via the TrilliumBiO partnership in 2026.

Oncobit firmographics

Firmographics
Name
Oncobit
Legal name
oncobit AG
Website
https://oncobit.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Oncobit AG is a Swiss precision oncology company developing digital PCR-based liquid biopsy assays and cloud-based analysis software for non-invasive monitoring of cancer patients, with initial focus on melanoma and uveal melanoma for clinical laboratories, hospitals, and pharmaceutical partners.
Ownership category
akta.pro rank

Oncobit industry classification

Industry
Product category
Cancer Molecular Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Liquid biopsy diagnostics
  • CtDNA monitoring assays
  • Digital PCR oncology
  • Cancer molecular diagnostics
  • Personalized cancer monitoring

Where Oncobit is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Oncobit business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Diagnostic Assays: Sale of cancer monitoring assay kits for melanoma and other cancer types. Tests detect specific genetic mutations using digital PCR technology from patient blood samples.
  2. Software Platform Access: Oncobit Portal provides secure access to the Oncobit Analyzer software for data analysis. Revenue generated through software licensing and platform access fees.
  3. Laboratory Services: Through TrilliumBiO partnership in US, Oncobit provides testing services via multi-accredited laboratory, enabling physicians to order monitoring tests without local infrastructure.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goB2B enterprise pricing for laboratories and hospitals

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Oncobit product offering

Product offering

Core offering

Oncobit develops and sells digital PCR-based liquid biopsy diagnostic assays combined with a CE-marked cloud analysis software (Oncobit PM Analyzer) for non-invasive cancer monitoring via circulating tumor DNA (ctDNA) detection from blood samples. The portfolio includes a five-marker melanoma panel (BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209), an uveal melanoma monitoring solution (Oncular™), and the Oncobit PM Personalized Monitoring platform, with CE-IVDR marking for the European market and US access via TrilliumBiO.

Product overview

Oncobit offers a unified portfolio centered on the Oncobit™ PM (Personalized Monitoring) platform for precision cancer care. The platform combines liquid biopsy-based diagnostic assays (including a five-marker melanoma panel and uveal melanoma test) with cloud-based data analysis software (Oncobit PM Analyzer) accessed via the Oncobit Portal. All assays run on Bio-Rad digital PCR infrastructure and carry CE-IVDR marking for the European market, with Oncular™ representing the US market offering for uveal melanoma monitoring.

Differentiator

Problem solved

Functional benefit

Brands

  • Oncular™: Uveal melanoma monitoring solution launched in partnership with TrilliumBiO for the US market, enabling real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw.
  • Oncobit™ PM

Products and services

  • Oncobit™ PM Platform Cloud-based personalized monitoring platform for cancer care that analyzes circulating tumor DNA (ctDNA) from liquid biopsy blood samples. The platform provides molecular insights for precise cancer monitoring and therapy optimization using digital PCR technology, scalable across multiple cancer types.
  • Oncobit™ PM Assays (Melanoma Panel) Digital PCR-based diagnostic assays for detecting and quantifying five critical melanoma cancer markers including BRAF V600 (V600D, V600E, V600E2, V600K, V600R), NRAS Q61 (Q61K, Q61L, Q61R), GNAQ Q209 (Q209L, Q209P), and GNA11 Q209 mutations. CE-IVDR marked, runs on Bio-Rad QX200/QX600 platforms with <24-hour turnaround time.
  • Oncobit PM Analyzer CE-marked proprietary cloud-based software designed to analyze data generated by Oncobit PM Assays. Accessed via the secure Oncobit Portal, providing standardized ctDNA data processing and reporting for clinical consistency.
  • Oncular™ Uveal melanoma monitoring solution providing real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw. Made available in the US market through TrilliumBiO's multi-accredited laboratory partnership.

Quantifiable outcome

  • <24 hour turnaround time for ctDNA analysis
  • +2 more outcomes

Companies that use Oncobit

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Oncobit technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature3 records

Oncobit partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • TrilliumBiOcoreChannel Partner/ Reseller/ Distributor · 9 December 2025Strategic partnership to bring Oncobit's uveal melanoma monitoring solution (Oncular) to the United States. TrilliumBiO provides multi-accredited laboratory services for nationwide test availability. Collaboration integrates Oncobit's Personalized Monitoring platform with TrilliumBiO's laboratory infrastructure.
  • ID SolutionscoreStrategic or Co-development Partner · 1 December 2025Strategic partnership combining ID Solutions' highly sensitive digital PCR biomarker detection technology with Oncobit's monitoring assays and analytical software. Aims to accelerate cancer diagnosis and enable more precise, real-time treatment monitoring in compliance with IVDR requirements.
  • Kempf und PfaltzcoreChannel Partner/ Reseller/ Distributor · 1 September 2025Swiss laboratory distributor for Oncobit PM assays. Customers in Switzerland can place orders through Kempf und Pfaltz for product distribution.
  • EADO-EUMelaRegminorStrategic or Co-development Partner · 1 January 2025Joint ctDNA project integrating circulating tumor DNA into routine melanoma follow-up. Evaluates clinical utility of Oncobit's CE-IVDR marked digital PCR solution to detect relapse and complement established monitoring approaches.
  • University Hospital Zurich / ETH ZurichcoreStrategic or Co-development Partner · 1 February 2024Oncobit is a HealthTech spin-off from University of Zurich. Founders are physicians and scientists from University Hospital Zurich and ETH Zurich. Ongoing research partnerships with clinical experts.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Oncobit competitors and assessment

Company assessment

Broad incumbents

  • Natera: Natera is a publicly traded molecular diagnostics company with Signatera, a leading personalized ctDNA-based MRD/monitoring test for solid tumors. Comparable in target market (oncology monitoring) and business model (tumor-informed liquid biopsy), but with a much broader assay menu and substantially greater commercial scale than Oncobit.
  • Guardant Health: Guardant Health offers Guardant360, one of the most widely used liquid biopsy comprehensive genomic profiling tests for advanced cancer, along with Guardant Reveal for MRD. Direct overlap in ctDNA-based oncology testing and biomarker monitoring, though Guardant operates at far greater scale using NGS rather than digital PCR.
  • Foundation Medicine (Roche): Foundation Medicine is a leading provider of comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) for solid tumors. Overlaps with Oncobit in oncology molecular diagnostics and biopharma companion diagnostics; Oncobit's chairman Bram Goorden previously served as President of International Business at Foundation Medicine.
  • Exact Sciences: Exact Sciences, known for Cologuard and Oncotype DX, has been expanding into liquid biopsy-based MRD/monitoring through its Cologuard Plus and Precision Oncology portfolio. Comparable in oncology monitoring business model and B2B sales to clinicians and biopharma, though operating at much greater scale across multiple cancer types.
  • Roche Diagnostics: Roche Diagnostics is a global leader in in-vitro diagnostics, including the cobas digital PCR platform and cell-free DNA-based oncology assays. Overlaps with Oncobit in molecular oncology diagnostics and IVD commercialization; board member Dr. Daniel Schoener previously held corporate leadership at Roche Diagnostics.
  • NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory services including liquid biopsy assays for therapy selection and disease monitoring. Overlaps with Oncobit in offering ctDNA-based tests to oncologists and biopharma clients, but operates a much broader multi-modality testing menu.

Direct peers

  • Sysmex Inostics: Sysmex Inostics specializes in highly sensitive digital PCR-based liquid biopsy testing for oncology, including the SafeSEQ and OncoBEAM platforms for ctDNA detection in melanoma and other solid tumors. Direct competitor in digital PCR-based oncology monitoring, with established biopharma and clinical laboratory customers.
  • Inivata (NeoGenomics): Inivata developed RaDaR, a tumor-informed personalized ctDNA MRD assay using digital PCR technology. Directly comparable to Oncobit's PM platform in technology (digital PCR-based ctDNA), use case (personalized cancer monitoring/MRD), and target customer (oncologists, biopharma). Now part of NeoGenomics.

Others

  • Bio-Rad Laboratories: Bio-Rad manufactures the QX200 and QX600 digital PCR systems on which Oncobit's PM Assays run. Comparable as enabling infrastructure for dPCR-based oncology testing; Bio-Rad also offers ddPCR reagents and certain assay kits for cell-free DNA research, partially overlapping with Oncobit's offering as a supplier/ecosystem partner.

Emerging players

  • ID Solutions: ID Solutions develops highly sensitive digital PCR-based biomarker detection technology and is a strategic partner and investor in Oncobit. Comparable in dPCR technology focus and oncology applications, and now commercially aligned with Oncobit for IVDR-compliant precision oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Oncobit compliance and trust

Trust signal

Compliance2 records

Oncobit financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncobit leadership team

Management profile

Number of profiles

Profiles12 records

Oncobit funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncobit M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncobit

What does Oncobit do?

Oncobit develops and sells digital PCR-based liquid biopsy diagnostic assays combined with a CE-marked cloud analysis software (Oncobit PM Analyzer) for non-invasive cancer monitoring via circulating tumor DNA (ctDNA) detection from blood samples. The portfolio includes a five-marker melanoma panel (BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209), an uveal melanoma monitoring solution (Oncular™), and the Oncobit PM Personalized Monitoring platform, with CE-IVDR marking for the European market and US access via TrilliumBiO.

Is Oncobit a public or private company?

Oncobit is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oncobit founded?

Oncobit was founded in 2019. It employs 11 to 50 people.

Where is Oncobit based?

Oncobit is headquartered in Schlieren, Switzerland, in the Europe region.

How does Oncobit make money?

Three revenue lines are on record. Diagnostic Assays are the primary driver. The others are software Platform Access and laboratory Services.

Who are Oncobit's main competitors?

Broad incumbents on record are Natera, Guardant Health, Foundation Medicine (Roche), Exact Sciences, Roche Diagnostics and NeoGenomics. Direct peers are Sysmex Inostics and Inivata (NeoGenomics). Bio-Rad Laboratories is listed as an others. ID Solutions is listed as an emerging player.

Does Oncobit have an API?

No public API is recorded for Oncobit.

What industry is Oncobit in?

Oncobit's product category is Cancer Molecular Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chOncobit launches uveal melanoma assay with TrilliumBiO in the USOncobit launched Oncular, a blood-based uveal melanoma monitoring assay, in the US with TrilliumBiO. The assay uses personalized digital PCR to quantify circulating tumor DNA from a routine blood draw. Financial terms were not disclosed.PR NewswireTrilliumBiO and Oncobit Launch Advanced Uveal Melanoma Monitoring Solution in the U.S.TrilliumBiO and Oncobit launched Oncular, a uveal melanoma monitoring assay, in the U.S. through TrilliumBiO's CLIA-certified laboratory. The test uses digital PCR to measure circulating tumor DNA, providing molecular residual disease status and treatment response signals. It aims to expand access to advanced molecular testing for this rare cancer.PR NewswireTrilliumBiO and Oncobit Partner to Bring Novel Uveal Melanoma Monitoring Solution to the U.S.TrilliumBiO and Oncobit announced a strategic partnership to bring Oncobit's uveal melanoma monitoring solution to the United States, making it available nationwide through TrilliumBiO's multi-accredited laboratory. The collaboration integrates Oncobit's Personalized Monitoring platform, which tracks circulating tumor DNA dynamics to predict treatment response and progression in metastatic uveal melanoma patients. Both companies aim to address a largely underserved patient population by providing physicians with molecular residual disease information to support more precise therapy decisions.VenturelabOncobit set for growth after CHF 1.9 million capital increaseOncobit AG, a precision oncology company based in Zurich, has secured over CHF 1.9 million in a new capital increase backed by existing and new investors including private business angels and strategic partner ID Solutions (IDS). The funding will support clinical validation work, regulatory progress, commercialization plans, and expansion into additional cancer indications and new markets. Founded in 2018 as a spinoff from the University of Zurich, the company offers cloud-based cancer monitoring solutions for pharmaceutical companies, clinical laboratories, and hospital institutions.startupticker.chOncobit set for growth after CHF 1.9 million capital increaseOncobit AG, a precision oncology company headquartered in Switzerland, has completed a financing round raising more than CHF 1.9 million from existing and new investors including strategic partner ID Solutions. The capital will fund clinical validation, regulatory activities, and expansion into additional cancer indications and new markets. Founded in 2018 as a spinoff from the University of Zurich, Oncobit has developed a liquid biopsy-based cancer monitoring platform and holds IVDR and ISO 13485 certifications.Venture KickOncobit secures CHF 1.47M in Pre-Series A Round to advance precision cancer solutionsOncobit, a Swiss precision medicine company, raised CHF 1.47 million in a pre-Series A round. The funds will support clinical melanoma research, expand its monitoring platform to colorectal cancer, and pursue US market entry. The investment aims to strengthen its position in cancer monitoring.VenturelabOncobit secures CHF 1.47M in Pre-Series A Round to advance precision cancer solutionsSwiss-based precision medicine company Oncobit secured CHF 1.47 million in a Pre-Series A financing round to support its growth strategy and product development. The funds will be utilized to advance clinical melanoma research, expand its monitoring platform to include colorectal cancer, and facilitate entry into the US market.startupticker.chCHF 1.5 million pre-series A funding for OncobitOncobit AG raised CHF 1.47 million in a pre-series A round from existing and new investors. The funds will support product development, clinical data generation for melanoma, and expansion into colorectal cancer and the US market. The company aims to set up for a Series A round to fuel global commercialization.VenturelabVenture Leaders Medtech 2022: Captain’s blog by Oncobit CEO Claudia Scheckel – VenturelabThe Venture Leaders Medtech 2022 team traveled to Boston in mid-June to connect with investors and experts. The team, led by Oncobit CEO Claudia Scheckel, arrived on Sunday, June 17th, and the week-long roadshow featured multiple Swiss medtech startups.